Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Dec 7;14 Suppl 4(Suppl 4):38-41.
doi: 10.1186/2047-783x-14-s4-38.

Lung surfactant alterations in pulmonary thromboembolism

A Calkovska  1 , D Mokra, V Calkovsky
Affiliations
Review

Lung surfactant alterations in pulmonary thromboembolism

A Calkovska et al. Eur J Med Res. .

Abstract

Beside neonatal respiratory distress syndrome, secondary surfactant deficiency may occur in patients with mature lungs. Recent studies revealed quantitative and qualitative changes of lung surfactant in pulmonary thromboembolism (PTE) concerning the total phospholipids content in BAL fluid, alterations in surfactant phospholipids classes and a large-to-small aggregates ratio. Reduced expression of surfactant protein A (SP-A) mRNA and SP-A in lung tissue after pulmonary embolism was found. Serum levels of SP-A were significantly higher in patients with PTE than in other lung diseases, except COPD. Surfactant changes in PTE may result from damage of type II cells by hypoxia, leakage of plasma proteins into the airspaces and/or by reactive oxygen species. They can contribute to lung atelectasis and edema, and a further reduction in oxygen saturation as seen in clinical picture of PTE. Surfactant changes are reliable marker of lung injury that might become a prognostic indicator in patients with pulmonary thromboembolism.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanisms and pathophysiological consequences of surfactant inactivation in pulmonary thromboembolism.
See this image and copyright information in PMC

References

    1. Robertson B, van Golde LMG, Batenburg JJ, editor. Pulmonary surfactant. From molecular biology to clinical practice. Amsterdam - London - New York - Tokyo, Elsevier; 1998. p. 753.
    1. Gross JN, Kellam M, Young J, Krishnasamy S, Dhand R. Separation of alveolar surfactant into subtypes. A comparison of methods. Am J Respir Crit Care Med. 2000;162:617–22. - PubMed
    1. Finley TN, Swenson WE, Clements JA, Gardner RE, Wright RR, Severinghaus JW. Changes in mechanical properties, appearance and surface activity of extracts of one lung following occlusion of its pulmonary artery in the dog. Physiologist. 1960;3(1):56–61.
    1. Sutnick AI, Soloff LA. Pulmonary arterial occlusion and surfactant production in humans. Ann Intern Med. 1967;67(3):549–55. - PubMed
    1. Nowak G, Glusa E, Herbst I, Schreiber S. Effect of bromhexine on microthrombosis in animal experiments. Biomed Biochim Acta. 1985;44(3):475–84. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources